Termination of lung inflammation by MyD88 alternative splicing
Funded at National Jewish Health · NIH-11388744 · Data updated 2026-11-12
A study in mice is examining how a gene splice variant called MyD88-S might control lung inflammation related to ARDS, with potential to identify new ways to prevent chronic lung inflammation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | National Jewish Health NIH-funded |
| Lab location | 1 site (Denver, United States) |
| Project start | July 10, 2026 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,559,468 |
| NIH project number | 1R01HL186673-01 |
| Project ID | NIH-11388744 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be patients with ARDS or at-risk individuals in whom therapies targeting inflammatory signaling could be relevant in the future.
✕Less likely to help
This study uses a mouse model and does not involve current patient care or directly testing therapies in people.
What this research studies
This project explores how alternative splicing of the MyD88 gene could switch the inflammatory response in the lungs, potentially reducing harmful chronic inflammation in conditions like ARDS. Researchers created a mouse model lacking the MyD88-S splice form to see how its absence affects NF-κB and AP-1 signaling during lung inflammation. The team will compare outcomes in these mice to normal mice, focusing on inflammatory markers, lung tissue changes, and overall lung function. If MyD88-S acts as a regulator rather than a simple inhibitor, this work could reveal new targets to modulate lung inflammation in patients with ARDS.
Why it matters
Potential benefit: If successful, the findings could lead to new strategies to prevent or dampen damaging lung inflammation in ARDS.
How similar studies have gone: Prior work suggests MyD88-S can influence inflammatory signaling, but this study tests a previously unexamined in vivo role, making findings promising yet exploratory.
Where this research is happening
-
National Jewish Health
Denver, United States Active
Researchers
- Principal investigator: Alper, Scott — National Jewish Health
- Study coordinator: Alper, Scott
Related research
Other NIH-funded projects on the same topics.
-
Predictive models for BeS and CBD in exposed workers
Aimed at people exposed to beryllium, this project will build models to identify who is at risk for beryllium sensitization and Chronic Beryllium Disease using lung samples and data.
-
Understanding how early skin biology affects the development of allergies in children
A study with infants and young children aims to understand why some kids with eczema (atopic dermatitis) go on to develop food allergies and asthma, by looking at skin biology and immune patterns still early in life.
-
Rare airway cells and how they affect lung infections after a viral illness
This NIH grant looks at a rare airway cell type called M cells to see how they influence secondary bacterial infections after a viral lung illness.
-
Obinutuzumab for CTD-Related Interstitial Lung Disease in adults
This project tests whether the anti-B cell therapy obinutuzumab can help adults with connective tissue disease–related ILD who are on mycophenolate therapy.
-
Effects of Temperature Fluctuation on the Skin Barrier (K08)
A clinician-scientist is being mentored over 5 years to understand how changes in temperature affect the skin barrier and the development of allergies in children.
-
Precision tapering of dupilumab in asthma for safer, cost-saving interval extension
We’re testing if adults with well-controlled asthma on dupilumab can safely extend the time between injections to reduce costs and burden.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.